MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/jcm13010284

Медицинская библиотека · Journal of clinical medicine · 2024

Multiparametric Monitoring of Disease Progression in Contemporary Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy Initiating Tafamidis Treatment.

Ney Svenja, Gertz Roman Johannes, Pennig Lenhard, Nies Richard J, Holtick Udo, Völker Linus A, Wunderlich Gilbert, Seuthe Katharina, Hohmann Christopher, Metze Clemens, Nähle Claas Philip, von Stein Jennifer, Brüwer Monique, Ten Freyhaus Henrik, Pfister Roman

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Recently, a disease modifying therapy has become available for transthyretin amyloid cardiomyopathy (ATTR-CM). A validated monitoring concept of treatment is lacking, but a current expert consensus recommends three clinical domains (clinical, biomarker and ECG/imaging) assessed by several measurable features to define disease progression.

METHODS

We retrospectively analyzed data of wild-type ATTR-CM patients initiating tafamidis therapy assessed within our local routine protocol at baseline and 6-months follow-up with respect to the frequency of values beyond the proposed thresholds defining disease progression. Additionally, associations of cardiac magnetic resonance (CMR) tomography with clinical domains were examined within a subgroup.

RESULTS

Sixty-two ATTR-CM patients were included (88.7% male, mean age 79 years). In total, 16.1% of patients had progress in the clinical and functional domain, 33.9% in the biomarker domain and 43.5% in the imaging/electrocardiography (ECG) domain, with the latter driven by deterioration of the diastolic dysfunction grade and global longitudinal strain. In total, 35.5% of patients showed progress in none, 35.5% in one, 29.0% in two and no patient in three domains, the latter indicating overall disease progression. A subgroup analysis of twenty-two patients with available baseline and follow-up CMR data revealed an increase in CMR-based extracellular volume by more than 5% in 18.2% of patients, with no significant correlation with progress in one of the clinical domains.

CONCLUSIONS

We provide first frequency estimates of the markers of disease progression according to a recent expert consensus statement, which might help refine the multiparametric monitoring concept in patients with ATTR-CM.

Для цитирования: Ney Svenja, Gertz Roman Johannes, Pennig Lenhard, Nies Richard J, Holtick Udo, Völker Linus A, Wunderlich Gilbert, Seuthe Katharina, Hohmann Christopher, Metze Clemens, Nähle Claas Philip, von Stein Jennifer, Brüwer Monique, Ten Freyhaus Henrik, Pfister Roman. Multiparametric Monitoring of Disease Progression in Contemporary Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy Initiating Tafamidis Treatment.. Journal of clinical medicine. 2024. DOI: 10.3390/jcm13010284.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.